PMS45 - COST PER RESPONDER ANALYSIS FOLLOWING A 48-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ADALIMUMAB FROM THE PORTUGUESE PAYER PERSPECTIVE
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1759
https://www.valueinhealthjournal.com/article/S1098-3015(18)35061-7/fulltext
Title :
PMS45 - COST PER RESPONDER ANALYSIS FOLLOWING A 48-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ADALIMUMAB FROM THE PORTUGUESE PAYER PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35061-7&doi=10.1016/j.jval.2018.09.1759
First page :
Section Title :
Open access? :
No
Section Order :
1125